Search

Your search keyword '"Arslan, Shukaib"' showing total 10 results
Start Over Author "Arslan, Shukaib" Publisher wiley
10 results on '"Arslan, Shukaib"'

1. Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID ‐19: A retrospective single‐center experience

Author

Amanam, Idoroenyi, primary, Yao, Janny, additional, Puing, Alfredo, additional, Tsai, Ni‐Chun, additional, Samuels, Diana, additional, Ngo, Dat, additional, Ho, Stephanie, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Arslan, Shukaib, additional, Artz, Andrew, additional, Htut, Myo, additional, Koller, Paul, additional, Salhotra, Amandeep, additional, Sandhu, Karamjeet, additional, Nikolaenko, Liana, additional, Pawlowska, Anna, additional, Shouse, Geoffrey, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Forman, Stephen, additional, Nakamura, Ryotaro, additional, Dadwal, Sanjeet, additional, and Al Malki, Monzr M., additional

Published
2023
Full Text
View/download PDF

2. High Response Rates and Transition to Transplant after Novel Targeted and Cellular Therapies in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia with Philadelphia‐Like Fusions

Author

Aldoss, Ibrahim, primary, Afkhami, Michelle, additional, Yang, Dongyun, additional, Gu, Zhaohui, additional, Mokhtari, Sally, additional, Shahani, Shilpa, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Koller, Paul, additional, Arslan, Shukaib, additional, Tomasian, Vanina, additional, Al Malki, Monzr M., additional, Artz, Andrew, additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Ball, Brian, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Becker, Pamela S., additional, Stewart, Forrest M., additional, Curtin, Peter, additional, Smith, Eileen, additional, Telatar, Milhan, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Nakamura, Ryotaro, additional, and Pullarkat, Vinod, additional

Published
2023
Full Text
View/download PDF

3. Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis

Author

La Rosa, Corinna, primary, Aldoss, Ibrahim, additional, Park, Yoonsuh, additional, Yang, Dongyun, additional, Zhou, Qiao, additional, Gendzekhadze, Ketevan, additional, Kaltcheva, Teodora, additional, Rida, Wasima, additional, Dempsey, Shannon, additional, Arslan, Shukaib, additional, Artz, Andrew, additional, Ball, Brian, additional, Nikolaenko, Liana, additional, Pullarkat, Vinod A., additional, Nakamura, Ryotaro, additional, and Diamond, Don J., additional

Published
2023
Full Text
View/download PDF

4. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

Author

Aldoss, Ibrahim, primary, Otoukesh, Salman, additional, Zhang, Jianying, additional, Mokhtari, Sally, additional, Ngo, Dat, additional, Mojtahedzadeh, Mona, additional, Al Malki, Monzr M., additional, Salhotra, Amandeep, additional, Ali, Haris, additional, Aribi, Ahmed, additional, Sandhu, Karamjeet S., additional, Arslan, Shukaib, additional, Koller, Paul, additional, Ball, Brian, additional, Stewart, Forrest, additional, Curtin, Peter, additional, Artz, Andrew, additional, Nakamura, Ryotaro, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Stein, Anthony S., additional, and Pullarkat, Vinod, additional

Published
2021
Full Text
View/download PDF

5. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax ( HMA‐Ven ) or liposomal daunorubicin‐cytarabine ( CPX ‐351)

Author

Salhotra, Amandeep, primary, Aribi, Ahmed, additional, Ngo, Dat, additional, Zhang, Jianying, additional, Sandhu, Karamjeet, additional, Al‐Malki, Monzr, additional, Ali, Haris, additional, Koller, Paul, additional, Arslan, Shukaib, additional, Budde, Elizabeth, additional, Khaled, Samer, additional, Dadwal, Sanjeet, additional, Snyder, David S., additional, Artz, Andrew, additional, Forman, Stephen, additional, Nakamura, Ryotaro, additional, Stein, Anthony, additional, Marcucci, Guido, additional, Aldoss, Ibrahim, additional, and Pullarkat, Vinod, additional

Published
2021
Full Text
View/download PDF

6. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemia

Author

Arslan, Shukaib, primary, Zhang, Jianying, additional, Dhakal, Prajwal, additional, Moran, Jenna, additional, Naidoo, Nuthana, additional, Lombardi, Jennifer, additional, Pullarkat, Vinod, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Yaghmour, George, additional, Bhatt, Vijaya R., additional, Fathi, Amir T., additional, and Aldoss, Ibrahim, additional

Published
2020
Full Text
View/download PDF

7. Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia

Author

Badar, Talha, primary, Szabo, Aniko, additional, Dinner, Shira, additional, Liedtke, Michaela, additional, Burkart, Madelyn, additional, Shallis, Rory M., additional, Yurkiewicz, Ilana R., additional, Kuo, Eric, additional, Khan, Muhammad Ali, additional, Balasubramanian, Suresh, additional, Yang, Jay, additional, Hefazi, Mehrdad, additional, Podoltsev, Nikolai, additional, Patel, Anand, additional, Curran, Emily, additional, Wang, Amy, additional, Arslan, Shukaib, additional, Aldoss, Ibrahim, additional, Siebenaller, Caitlin, additional, Mattison, Ryan J., additional, Litzow, Mark R., additional, Wadleigh, Martha, additional, Advani, Anjali S., additional, and Atallah, Ehab, additional

Published
2020
Full Text
View/download PDF

8. Venetoclax and hypomethylating agents inFLT3‐mutated acute myeloid leukemia

Author

Aldoss, Ibrahim, primary, Zhang, Jianying, additional, Mei, Matthew, additional, Al Malki, Monzr M, additional, Arslan, Shukaib, additional, Ngo, Dat, additional, Aribi, Ahmed, additional, Ali, Haris, additional, Sandhu, Karamjeet, additional, Salhotra, Amandeep, additional, Koller, Paul, additional, Khaled, Samer, additional, Artz, Andrew, additional, Snyder, David, additional, Nakamura, Ryotaro, additional, Forman, Stephen J, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, and Pullarkat, Vinod, additional

Published
2020
Full Text
View/download PDF

9. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.

Author

Aldoss I, Otoukesh S, Zhang J, Mokhtari S, Ngo D, Mojtahedzadeh M, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Koller P, Ball B, Stewart F, Curtin P, Artz A, Nakamura R, Marcucci G, Forman SJ, Stein AS, and Pullarkat V

Subjects
Humans, Recurrence, Retrospective Studies, Antibodies, Bispecific therapeutic use, Disease Progression, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
Abstract

Background: Blinatumomab has demonstrated encouraging activity in relapsed/refractory (r/r) and minimal residual disease-positive (MRD+) acute lymphoblastic leukemia (ALL). Extramedullary disease (EMD) relapse or relapse with CD19- disease has been observed after blinatumomab therapy in patients with r/r or MRD+ ALL. However, the pathophysiology and risk factors of treatment failure are not fully understood., Methods: This study retrospectively reviewed the outcomes of adult patients with B-cell ALL treated with blinatumomab (n = 132) for either r/r (n = 103) or MRD+ disease (n = 29) at the authors' center (2013-2021) and analyzed factors associated with treatment response and EMD failure., Results: The overall response rate was 64%. A lower marrow blast burden before blinatumomab (P = .049) and no history of previous EMD (P = .019) were significantly associated with a higher response. Among the patients who responded to blinatumomab, 56% underwent consolidation with allogeneic transplantation. Blinatumomab failure was observed in 89 patients; 43% of these patients (n = 38) either progressed or relapsed at extramedullary sites. A history of extramedullary involvement (53% vs 24%; P = .005) and retention of CD19 expression at the time of relapse/progression (97% vs 74%; P = .012) were associated with a higher risk for extramedullary failure. Central nervous system (CNS) failure after blinatumomab was encountered in 39% of the patients with EMD., Conclusions: A history of EMD predicted an inferior response to blinatumomab therapy with a higher risk for relapse/progression at extramedullary sites (particularly CNS). Consolidation with allogenic transplantation in patients who primarily responded to blinatumomab did not abrogate the risk of extramedullary relapse. The incorporation of extramedullary assessment and the intensification of CNS prophylaxis may help in addressing extramedullary failure., Lay Summary: Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites. Most extramedullary failure cases retain CD19 expression., (© 2021 American Cancer Society.)

Published
2022
Full Text
View/download PDF

10. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.

Author

Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, and Atallah E

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Bispecific adverse effects, Antineoplastic Agents, Immunological adverse effects, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Hematopoietic Stem Cell Transplantation statistics & numerical data, Humans, Inotuzumab Ozogamicin adverse effects, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Remission Induction, Retrospective Studies, Treatment Outcome, Withholding Treatment statistics & numerical data, Young Adult, Antibodies, Bispecific administration & dosage, Antineoplastic Agents, Immunological administration & dosage, Inotuzumab Ozogamicin administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Background: The availability of novel agents (NAs), including blinatumomab and inotuzumab ozogamicin (InO), has improved the outcomes of patients with relapsed/refractory (RR) B-cell acute lymphoblastic leukemia (ALL). Because of the relative effectiveness, it is often a challenge for clinicians to determine how to best sequence these NAs with respect to efficacy and toxicity., Methods: In this multicenter, retrospective study of patients with RR ALL treated with blinatumomab, InO, or both, their efficacy as a first or second NA was compared., Results: Among 276 patients, 221 and 55 received blinatumomab and InO, respectively, as a first NA therapy. The complete remission (CR)/complete remission with incomplete count recovery (CRi) rate was 65% and 67% for the blinatumomab and InO groups, respectively (P = .73). The rate of treatment discontinuation due to adverse events was 4% and 7% in the blinatumomab and InO groups, respectively. Ninety-two patients (43%) in the blinatumomab group and 13 patients (29%) in the InO group proceeded with allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) was 15 and 11.6 months in the blinatumomab and InO groups, respectively. A subset analysis was performed for 61 patients who received both NAs (blinatumomab and then InO [n = 40] or InO and then blinatumomab [n = 21]). The CR/CRi rate was 58% for patients who received InO as the second NA and 52% for patients who received blinatumomab as the second NA. The median OS was 10.5 for patients who received InO as the second NA and 5.9 months for patients who received blinatumomab as the second NA (P = .09)., Conclusions: Although the limited power of this study to detect a significant difference between subgroups is acknowledged, the data suggest that blinatumomab and InO may have comparable efficacy as a first or second NA therapy in RR ALL., (© 2020 American Cancer Society.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results